SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

European Commission Approves Roche Drug For Age-Related Macular Degeneration

The European Commission has approved Roche Holding AG's Susvimo for the treatment of neovascular age-related macular degeneration (AMD).

ROPC.S

Sept 21 (Reuters) — Roche Holding AG said the European Commission has approved Susvimo for the treatment of neovascular age-related macular degeneration (nAMD). The company said the phase III Archway study showed Susvimo maintained vision equivalent to monthly injections. Further company coverage: ROPC.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587785269;)

Related stories